Pterostilbene Improves Apoptosis, Inflammation, and Autophagy of Osteoarthritis Chondrocytes Through the

Lei Zhou1, Cong Cong Sun1, Fa Juan Shen2

  • 1Department of Hand Surgery, The Second Affiliated Hospital of Shandong First Medical University, Tai'an City, China.

Insights

Pterostilbene protects against osteoarthritis by inhibiting the (rat sarcoma virus/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase) pathway, reducing chondrocyte injury and inflammation.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage breakdown and inflammation.
  • Chondrocyte apoptosis and extracellular matrix degradation are key pathological features of OA.
  • The (rat sarcoma virus/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase) (RAS/RAF/MEK/ERK) pathway plays a critical role in OA pathogenesis.

Purpose of the Study:

  • To investigate the therapeutic effects of pterostilbene on chondrocyte injury in OA.
  • To elucidate the underlying molecular mechanisms, specifically the regulation of the RAS/RAF/MEK/ERK pathway by pterostilbene.

Main Methods:

  • Established OA animal models and cultured interleukin-1β-treated chondrocytes.
  • Administered pterostilbene to in vivo and in vitro models.
  • Assessed cartilage damage, chondrocyte viability, apoptosis, and autophagosome formation.
  • Measured inflammatory factors and key proteins in the RAS/RAF/MEK/ERK pathway using ELISA and Western blot/RT-PCR.

Main Results:

  • Pterostilbene attenuated cartilage injury, improved cartilage morphology, and reduced inflammatory factors in OA mice.
  • Pterostilbene decreased interleukin-1β-induced chondrocyte injury, enhanced viability, reduced apoptosis, and promoted autophagy.
  • Pterostilbene inhibited the expression of MMP-1, MMP-13, cleaved caspase-3, p-p65, and p62, while promoting autophagy-related gene 5 expression.
  • Pterostilbene effectively blocked RAS/RAF/MEK/ERK pathway activation.

Conclusions:

  • Pterostilbene demonstrates significant chondroprotective effects in OA.
  • The therapeutic mechanism involves the inhibition of the RAS/RAF/MEK/ERK pathway.
  • Pterostilbene holds potential as a therapeutic agent for osteoarthritis treatment.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K